Cargando…

Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study

BACKGROUND: HBV DNA is the most important molecular marker in hepatitis B, used to determine treatment indication and monitoring. Most patients require lifelong hepatitis B virus (HBV) management, thus viral load (VL) monitoring may be performed at different laboratories, with different HBV assays,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maasoumy, Benjamin, Bremer, Birgit, Lehmann, Patrick, Marins, Ed G., Michel-Treil, Véronique, Simon, Christian O., Njoya, Merlin, Cornberg, Markus, Paxinos, Ellen, Manns, Michael P., Vermehren, Johannes, Sarrazin, Christoph, Sohn, Ji Yeon, Cho, Yunjung, Wedemeyer, Heiner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557192/ https://www.ncbi.nlm.nih.gov/pubmed/28835775 http://dx.doi.org/10.1177/1756283X17722745

Ejemplares similares

Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms
por: Vermehren, Johannes, et al.
Publicado: (2017)

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
por: Mücke, Marcus M., et al.
Publicado: (2019)

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis
por: Maasoumy, Benjamin, et al.
Publicado: (2014)

Effects of renin–angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis
por: Tergast, Tammo L., et al.
Publicado: (2023)

Nosocomial infections in female compared with male patients with decompensated liver cirrhosis
por: Griemsmann, Marie, et al.
Publicado: (2022)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C
por: Markova, Antoaneta A., et al.
Publicado: (2014)

Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response
por: Meyer, Manuela F, et al.
Publicado: (2007)

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response
por: Cloherty, Gavin, et al.
Publicado: (2016)

HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination
por: Maasoumy, Benjamin, et al.
Publicado: (2020)

Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
por: Maasoumy, Benjamin, et al.
Publicado: (2013)

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience
por: Sandmann, Lisa, et al.
Publicado: (2021)

Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection
por: Wranke, Anika, et al.
Publicado: (2023)

Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing
por: Stahl, Yannick, et al.
Publicado: (2023)

Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites
por: Tergast, Tammo L., et al.
Publicado: (2018)

Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells
por: Schlaphoff, Verena, et al.
Publicado: (2011)

Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites
por: Tergast, Tammo L., et al.
Publicado: (2023)

Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany
por: Hillert, Annika, et al.
Publicado: (2021)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity
por: Strunz, Benedikt, et al.
Publicado: (2018)

Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study
por: Maasoumy, Benjamin, et al.
Publicado: (2022)

Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA
por: Heidrich, Benjamin, et al.
Publicado: (2014)

Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis
por: Kimmann, Markus, et al.
Publicado: (2019)

Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS
por: Stockhoff, Lena, et al.
Publicado: (2021)

Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C
por: Owusu Sekyere, Solomon, et al.
Publicado: (2015)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections
por: Malone, David F. G., et al.
Publicado: (2017)

Breakthroughs in hepatitis C research: from discovery to cure
por: Manns, Michael P., et al.
Publicado: (2022)

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
por: Wiegand, Steffen B., et al.
Publicado: (2015)

Development and evaluation of a baseline-event-anticipation score for hepatitis delta
por: Calle Serrano, B, et al.
Publicado: (2014)

Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review
por: Sperle, Ida, et al.
Publicado: (2020)

Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy
por: Schulte, Benjamin, et al.
Publicado: (2020)

New hepatitis C therapies in clinical development
por: Vermehren, Johannes, et al.
Publicado: (2011)

Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy
por: Soon, Chai Fen, et al.
Publicado: (2019)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry
por: Tacke, Frank, et al.
Publicado: (2022)

Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites
por: Schultalbers, Marie, et al.
Publicado: (2020)

Strategietreffen: Virushepatitis in Deutschland eliminieren – Was ist zu tun?
por: Tergast, T. L., et al.
Publicado: (2023)

Public employees in South-Western Norway using an e-bike or a regular bike for commuting – A cross-sectional comparison on sociodemographic factors, commuting frequency and commuting distance
por: Jahre, Anette B., et al.
Publicado: (2019)

Soluble immune markers in the different phases of chronic hepatitis B virus infection
por: Wiegand, Steffen B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fr3o2p7kejbq6i8nig4h530b0e